中
Home
About Us
About Haihe Biopharma
Mission and Vision
Management Team
Company Milestones
Awards
Research & Development
Strong, Innovation-driven R&D Capabilities
R&D Pipeline
Investor Partnerships & BD
Investors
Business Development
News Center
News
Interview
Career
Our Culture
Salary and Benefits
Employee
Job
中文
日本語
News Center
Press Release
页索引超出范围
Press Release
2020.03.18
HaiHe Biopharma Obtains the Global Exclusive License of STING Activator from Shanghai Institute of Materia Medica
2020.03.11
First patient dosed in Japan with HaiHe Biopharma’s Glumetinib c-Met inhibitor
2020.01.24
First patient dosed in the United States with HaiHe Biopharma’s innovative drug ERK inhibitor
2019.12.11
HaiHe Biopharma obtains the CTN Acknowledgement from Japan PMDA for its Glumetinib c-Met Inhibitor
2019.12.10
HaiHe Biopharma Obtains the IND Implied License from FDA for its Innovative Drug EZH1/2 Dual Inhibitor
2019.09.05
First subject dosed in the Phase III clinical trial of oral paclitaxel RMX3001 by HaiHe Biopharma in the treatment of breast cancer in China
2019.08.30
First patient dosed in the Phase Ib clinical trial of Lucitanib by HaiHe Biopharma combined with Toripalimab
2019.08.27
First patient dosed in the Phase Ib clinical trial of Glumetinib by HaiHe Biopharma in the treatment of MET-positive advanced non-small cell lung cancer
4
5
6
Interview
|
Legal statement
|
Disclaimers
|
Contact
|
Follow Us
©
2020 All Rights Reserved Haihe Biopharma Co., Ltd.
沪ICP备12016151号-1
.jpg)
